Evidence map›Paper›PMID 27248321›Full record

ArticleOncotarget2016

Polymorphisms in TIM-3 and breast cancer susceptibility in Chinese women: A case-control study.

Zheng Wang, Xinghan Liu, Xijing Wang, Tie Chong, Shuai Lin, Meng Wang, Xiaobin Ma, Kang Liu, Peng Xu, Yanjing Feng and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. CD8Frontiers in immunology · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Tim-3 finds its place in the cancer immunotherapy landscape.Journal for immunotherapy of cancer · 2020
    Review
  8. Review
  9. Association betweenAnnals of translational medicine · 2019
    Article
  10. Review
  11. Functional variants ofFuture science OA · 2018
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Zheng WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xinghan LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xijing WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Tie ChongDepartment of Urologic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Shuai LinDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Meng WangDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Xiaobin MaDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Kang LiuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Peng XuDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Yanjing FengDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Zhijun DaiDepartment of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have found associations between polymorphisms in T cell immunoglobulin and mucin domain 3 (TIM-3) and increased risks of various cancers. However, the association between TIM-3 polymorphisms and breast cancer (BC) remains uncertain. In this study, a total of 560 BC patients and 583 age, sex, and ethnicity-matched healthy controls from Northwest China were included. The polymorphisms were genotyped using Sequenom MassARRAY. The expression level of TIM-3 protein was detected by immunohistochemistry. We observed rs10053538 had a significantly increased risk of BC, comparing with the wild-type genotype even after Bonferroni correction. In addition, the rs4704853 G>A variants were more frequent among BC patients than the controls (GA + AA vs. GG: OR = 1.32, 95% CI = 1.03-1.69, P = 0.026); However, the significance was lost after Bonferroni correction (P = 0.078). Furthermore, rs10053538 was associated with lymph node metastasis. Age stratification revealed that among patients aged <49 years, those with the rs4704853 GA/AA genotype had a higher risk of BC; But there was no difference when Bonferroni correction was conducted. Immunohistochemical analysis showed that the expression of TIM-3 protein in the breast cancer tissues was higher in patients carrying the rs10053538 GT+TT genotype than those with GG genotype (P = 0.012). However, we failed to find any difference between BC patients and controls in any rs1036199 genetic model. These findings suggested that rs10053538 in TIM-3 might increase susceptibility to BC and promote the progression of BC in Chinese women.

Indexed as

AdultAgedAsian PeopleBreast NeoplasmsCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHepatitis A Virus Cellular Receptor 2HumansMiddle AgedPolymorphism, Single NucleotideHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2breast cancercase-control studypolymorphismTIM-3

Identifiers

PMID27248321
PMCPMC5190054
OpenAlexW2397956340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.